



## Curriculum Vitae

Personal information **Peter Munch Andersen**

### Work experience

---

1. Employer: Umeå University/ Umeå University Hospital
  - Start date: 032010
  - End date:
  - Position: Professor of Neurology/ Senior Neurologist
  - Activities:
  - Country: Sweden

### Education and training

---

1. Subject: University of Copenhagen
  - Start date: 081982
  - End date: 061990
  - Qualification: Medical Degree
  - Organisation:
  - Country: Denmark
2. Subject: Gällivare Hospital
  - Start date: 091990
  - End date: 051992
  - Qualification: License to practise medicine
  - Organisation: Internship
  - Country: Sweden
3. Subject: Umeå University Hospital
  - Start date: 061992
  - End date: 051997
  - Qualification: Board certified specialist in clinical neurology
  - Organisation: 5 year residency
  - Country: Sweden
4. Subject: Umeå University
  - Start date: 031993
  - End date: 111997
  - Qualification: Doctoral Dissertation (thesis)
  - Organisation: Doctoral dissertation on the role of SOD1 clinical genetics and antioxidants in ALS.
  - Country: Sweden

### Additional information

---

- Publications** Peer-reviewed scientific publications from September 2014 => October 2022 Articles in refereed journals: 171 => 281 Number of citations: 6172 => 17 605 h\_index: 43 => 68 22 papers have been published in the NEJM (2), Lancet, Nature, Neuron and Science journals.
- Projects** Past clinical positions Internship 1990 09 – 1992 05 Gällivare Hospital Resident in neurology 1992 06 – 1997 06 Umeå University Hospital Junior consultant neurologist 1997 07 – 1998 09 Umeå University Hospital 1999 10 – 2002 03 Umeå University Hospital Senior Consultant Neurologist 2002 04 – present Umeå University Hospital Past academic positions Acting clinical lecturer in Clinical Neurology, UmU 1999\_10\_01 – 2001\_01\_19 Senior lecturer in Clinical Neurology, UmU 2001\_01\_20 \_ 2010\_03\_31 Visiting professor (part time), the ALS research group, Ulm University, Germany 2010\_04 \_ 2013\_03 & 2013\_07 – 2018\_12
- Memberships** Scientific Honors and Awards 1. Carlsberg Fellowship 12-month Research Stipend (The Carlsberg Research Foundation, 1987). 2. Warfinges Stipend Prize for best doctoral thesis at the medical faculty, Umeå University in the 5-year period 1994-1998 (Umeå University, 1999). 3. Frithiof Lennmalms Prize (The Swedish Society of Medicine, 1999). 4. The Charcot Investigator Prize (The International Motor Neurone Disease Association, 2000). 5. Eric K. Fernströms Award for young most promising scientists (Umeå University, 2001). 6. The National Swedish Patient Organization Neuroförbundet/NHR Grand Prize at the organizations 50 years anniversary in 2007 (NHR, 2007) 7. Ulla\_Carin Lindquist Foundation Award for excellent ALS Research, 2011 (UCLS, 2011) 8. Award from the National Patient Organization Neuroförbundet for outstanding clinical research involving ALS patients (NHR, 2012). 9. KAW Clinical Scholar I: 2016-2021 10. KAW Clinical Scholar II: 2022-2026 Commissions of Trust and Varia: 1. Member of the World Federation of Neurology (WFN) and the European Federation of Neurological Societies (EFNS, EAN) Scientist panels on amyotrophic lateral sclerosis, 2001 – ff 2. Chair of EFNSs special Task Force for establishing Evidence-based European Guidelines for Diagnosing, Treating and Managing Patients with ALS, 2003 – 2015. This Task Force published two peer-reviewed publications in journals and two book chapters on evidence based clinical guidelines for diagnosing and managing patients with ALS. With the establishment of the European Academy of Neurology (EAN) in 2015 a new task force with similar objectives was set up. I am the Swedish representative in this new EAN ALS Task Force. The EAN task force is preparing new pan-European guidelines for the clinical management of ALS patients and their relatives. 3. Member of the European ALS Research Consortium (ENCALS, formerly EALSC) executive committee (Nordic delegate) 2004 – present. 4. Member of ENCALS's scientific task force for genetics (administer the database www.alsod.org). 5. Member of the editorial boards of ALS and Frontotemporal Degeneration (2010 – present). 6. Member of the Research Board, the Medical Faculty, Umeå University, 2008-2011. 7. Scientific secretary and member of the board, The Swedish Neurological Association, 2007 – 2010. 8. Member of the Board of Physicians, Umeå University Hospital 2007 – 2010. 9. Member of the Ethical Review Board for Medical Research, 2002-2003 (FEK) & 2004-2019 (EPN) 10. Opponent at Bert Oosthuysse defence of doctoral

thesis Targeted deletion of the hypoxia\_response element in the VEGF promotor causes adult motor neuron degeneration, Katholieke Universiteit Leuven, Belgium, 2002. Opponent at Roland Månssons defence of doctoral thesis Calcium\_induced mitochondrial permeability transition in CNS\_derived mitochondria, Lund University 2010. 11. Scientific Advisor and grant reviewer for patient organizations in Great Britain (the MND/ALS Association, MND), Italy (ARISLA), USA (ALSA) and Sweden (UCLS). 12. Ad Hoc reviewer for the British Research Council (MRC), the French National Program of Clinical Research (PHRC), the Fondation Thierry Lathran, and the Karolinska Institute. 13. Reviewer for senior academic positions in Sweden and abroad (including for the chair of neurology at HSS/Weill\_Cornell University Medical Center, NY, USA, 2009). 14. On behalf of the Swedish National Board of Health and Welfare/Socialstyrelsen, I author the official Swedish information documents on ALS, with updates every third year ([www.sos.se](http://www.sos.se)). 15. Ad hoc scientific advisor for government agency The National Board for Assessing the use of Treatments and Interventions in Medicine (SBU, Statens beredning för medicinsk utvärdering). 16. Organizer of the 3rd. European ALS Research Conference (held in Umeå, June 10-12, 2005). 17. Invited speaker on many occasions including at the Russian Academy of Sciences (2000), the Berzelius Symposium (2006), and the International ALS Conference in Toronto (2007), where I gave the plenary opening lecture. 18. Since 2021, member of the ClinGen ALS Gene Curation Expert panel (a board of mostly US\_researchers established by the NiH to assess the pathogenicity of variants in the human genome). 19. Since 1994, I am the PI of 39 approved applications submitted to the Swedish Ethical Review Board for Medical Research (FEK, EPN, EPM) for conducting human clinical research. 20. Our discovery of loss\_of\_function mutations in TANK Binding Kinase\_1 as a cause of ALS earned a front\_cover view in Nature Neuroscience:

## Other Relevant Information